GSK plc reported that its FIRST trial for advanced ovarian cancer met its main goal of improving progression-free survival as of December 20, 2024, demonstrating the effectiveness of adding Jemperli to standard chemotherapy. This event is considered significant for the company, with a positive sentiment from investors; it belongs to the category of 'Major product launches or discontinuations.'